The Changes of Serum Soluble Intercellular Adhesion Molecule-1(ICAM-1) According to the Clinical Course of Graves' Disease Treated with Antithyroid Drug
- Author:
Jin Hong LEE
;
Jae Kyu SHIN
;
So Young BAK
;
Bong Soo AN
;
Bon Jeong KU
;
Mee Ae AHN
;
Jun Sik JEON
;
Young Kun KIM
;
Heung Kyu RO
- Publication Type:Original Article
- Keywords:
TBII(TSH Binding Inhibitory Immunoglobulin);
ICAM-1(Intercellular Adhesion Molecule-l)
- MeSH:
Antithyroid Agents;
Autoimmunity;
Enzyme-Linked Immunosorbent Assay;
Graves Disease;
Humans;
Intercellular Adhesion Molecule-1;
Lymphocytes;
Methimazole;
Methods;
Prognosis;
Propylthiouracil;
Thyroid Diseases;
Thyroid Gland;
Thyroiditis
- From:Journal of Korean Society of Endocrinology
1996;11(3):293-301
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background: TSH binding inhibiting imunoglobulins(TBII) are autoimmune antibody causing autoimmune thyroid diseases such as Graves disease or Hashimoto's thyroiditis, while intercellular adhesion molecule-1(ICAM-1) is known as a substance expressed at the site of autoimmune reaction in relation with lymphocyte infiltration. The serum TBII activity is used as an index of the disease course and prognosis of Graves disease treated with antithyroid drugs, propylthiouracil or methimazole. The aim of this study is to understand the change of serum ICAM-1 level according to the change of the degree of autoimmunity and clinical course of Graves disease. Methods: In order to study the change of soluble ICAM-1 and relationship to the immune mechanism of Graves' disease, we measured serum levels of TBII and ICAM-1 in patients(n 35) with Graves disease before and after treatment with antithyroid drugs and in relapsed patients using a highly sensitive ELISA method. Results: The serum levels of TBII and ICAM-1 were markedly elevated in patients with Graves disease before treatment than normal controls and there were good correlation between TBII and ICAM-1 level. In patients with normalized TBII levels after 22 months antithyroid drug treatment, the ICAM-1 levels became normal but in the patients with high serum TBII level showed high serum level of ICAM-1 even with clinical remission with same treatment. The serum levels of TBII and ICAM-1 in relapsed patients were elevated as those of patients before treatment. Conclusion: With the above results, we can conclude that not only the TBII level but seru ICAM-1 level also reflect the degree of autoimmune activity of Graves disease and may be used as an index of the disease course and prognosis of Graves disease treated with antithyroid drugs.
